202 related articles for article (PubMed ID: 18406614)
1. Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives.
Gillespie RJ; Adams DR; Bebbington D; Benwell K; Cliffe IA; Dawson CE; Dourish CT; Fletcher A; Gaur S; Giles PR; Jordan AM; Knight AR; Knutsen LJ; Lawrence A; Lerpiniere J; Misra A; Porter RH; Pratt RM; Shepherd R; Upton R; Ward SE; Weiss SM; Williamson DS
Bioorg Med Chem Lett; 2008 May; 18(9):2916-9. PubMed ID: 18406614
[TBL] [Abstract][Full Text] [Related]
2. Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives.
Gillespie RJ; Cliffe IA; Dawson CE; Dourish CT; Gaur S; Giles PR; Jordan AM; Knight AR; Lawrence A; Lerpiniere J; Misra A; Pratt RM; Todd RS; Upton R; Weiss SM; Williamson DS
Bioorg Med Chem Lett; 2008 May; 18(9):2920-3. PubMed ID: 18407496
[TBL] [Abstract][Full Text] [Related]
3. Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines.
Gillespie RJ; Cliffe IA; Dawson CE; Dourish CT; Gaur S; Jordan AM; Knight AR; Lerpiniere J; Misra A; Pratt RM; Roffey J; Stratton GC; Upton R; Weiss SM; Williamson DS
Bioorg Med Chem Lett; 2008 May; 18(9):2924-9. PubMed ID: 18411049
[TBL] [Abstract][Full Text] [Related]
4. The discovery and synthesis of novel adenosine receptor (A(2A)) antagonists.
Matasi JJ; Caldwell JP; Hao J; Neustadt B; Arik L; Foster CJ; Lachowicz J; Tulshian DB
Bioorg Med Chem Lett; 2005 Mar; 15(5):1333-6. PubMed ID: 15713381
[TBL] [Abstract][Full Text] [Related]
5. Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists.
Vu CB; Shields P; Peng B; Kumaravel G; Jin X; Phadke D; Wang J; Engber T; Ayyub E; Petter RC
Bioorg Med Chem Lett; 2004 Oct; 14(19):4835-8. PubMed ID: 15341934
[TBL] [Abstract][Full Text] [Related]
6. Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines.
Gillespie RJ; Bamford SJ; Botting R; Comer M; Denny S; Gaur S; Griffin M; Jordan AM; Knight AR; Lerpiniere J; Leonardi S; Lightowler S; McAteer S; Merrett A; Misra A; Padfield A; Reece M; Saadi M; Selwood DL; Stratton GC; Surry D; Todd R; Tong X; Ruston V; Upton R; Weiss SM
J Med Chem; 2009 Jan; 52(1):33-47. PubMed ID: 19072055
[TBL] [Abstract][Full Text] [Related]
7. Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
Vu CB; Peng B; Kumaravel G; Smits G; Jin X; Phadke D; Engber T; Huang C; Reilly J; Tam S; Grant D; Hetu G; Chen L; Zhang J; Petter RC
J Med Chem; 2004 Aug; 47(17):4291-9. PubMed ID: 15294001
[TBL] [Abstract][Full Text] [Related]
8. Antagonists of the human A(2A) receptor. Part 6: Further optimization of pyrimidine-4-carboxamides.
Gillespie RJ; Bamford SJ; Clay A; Gaur S; Haymes T; Jackson PS; Jordan AM; Klenke B; Leonardi S; Liu J; Mansell HL; Ng S; Saadi M; Simmonite H; Stratton GC; Todd RS; Williamson DS; Yule IA
Bioorg Med Chem; 2009 Sep; 17(18):6590-605. PubMed ID: 19695884
[TBL] [Abstract][Full Text] [Related]
9. Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease.
Weiss SM; Benwell K; Cliffe IA; Gillespie RJ; Knight AR; Lerpiniere J; Misra A; Pratt RM; Revell D; Upton R; Dourish CT
Neurology; 2003 Dec; 61(11 Suppl 6):S101-6. PubMed ID: 14663021
[TBL] [Abstract][Full Text] [Related]
10. Studies on adenosine A2a receptor antagonists: comparison of three core heterocycles.
Vu CB; Pan D; Peng B; Sha L; Kumaravel G; Jin X; Phadke D; Engber T; Huang C; Reilly J; Tam S; Petter RC
Bioorg Med Chem Lett; 2004 Oct; 14(19):4831-4. PubMed ID: 15341933
[TBL] [Abstract][Full Text] [Related]
11. Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines.
Neustadt BR; Hao J; Lindo N; Greenlee WJ; Stamford AW; Tulshian D; Ongini E; Hunter J; Monopoli A; Bertorelli R; Foster C; Arik L; Lachowicz J; Ng K; Feng KI
Bioorg Med Chem Lett; 2007 Mar; 17(5):1376-80. PubMed ID: 17236762
[TBL] [Abstract][Full Text] [Related]
12. Biaryl and heteroaryl derivatives of SCH 58261 as potent and selective adenosine A2A receptor antagonists.
Shah U; Boyle CD; Chackalamannil S; Neustadt BR; Lindo N; Greenlee WJ; Foster C; Arik L; Zhai Y; Ng K; Wang S; Monopoli A; Lachowicz JE
Bioorg Med Chem Lett; 2008 Jul; 18(14):4199-203. PubMed ID: 18562199
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of novel 7-imino-2-thioxo-3,7-dihydro-2H-thiazolo [4,5-d] pyrimidine derivatives as adenosine A2A receptor antagonists.
Luthra PM; Mishra CB; Jha PK; Barodia SK
Bioorg Med Chem Lett; 2010 Feb; 20(3):1214-8. PubMed ID: 20018509
[TBL] [Abstract][Full Text] [Related]
14. Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of Parkinson's disease.
Shah U; Hodgson R
Curr Opin Drug Discov Devel; 2010 Jul; 13(4):466-80. PubMed ID: 20597030
[TBL] [Abstract][Full Text] [Related]
15. Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists.
Peng H; Kumaravel G; Yao G; Sha L; Wang J; Van Vlijmen H; Bohnert T; Huang C; Vu CB; Ensinger CL; Chang H; Engber TM; Whalley ET; Petter RC
J Med Chem; 2004 Dec; 47(25):6218-29. PubMed ID: 15566292
[TBL] [Abstract][Full Text] [Related]
16. Antiparkinsonian effects of novel adenosine A(2A) receptor antagonists.
Drabczyńska A; Zygmunt M; Sapa J; Filipek B; Müller CE; Kieć-Kononowicz K
Arch Pharm (Weinheim); 2011 Jan; 344(1):20-7. PubMed ID: 21213348
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.
Slee DH; Zhang X; Moorjani M; Lin E; Lanier MC; Chen Y; Rueter JK; Lechner SM; Markison S; Malany S; Joswig T; Santos M; Gross RS; Williams JP; Castro-Palomino JC; Crespo MI; Prat M; Gual S; Díaz JL; Wen J; O'Brien Z; Saunders J
J Med Chem; 2008 Feb; 51(3):400-6. PubMed ID: 18189346
[TBL] [Abstract][Full Text] [Related]
18. Adenosine A2A receptor antagonists as novel anti-Parkinsonian agents: a review of structure-activity relationships.
Azam F; Ibn-Rajab IA; Alruiad AA
Pharmazie; 2009 Dec; 64(12):771-95. PubMed ID: 20095134
[TBL] [Abstract][Full Text] [Related]
19. Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice.
Smith KM; Browne SE; Jayaraman S; Bleickardt CJ; Hodge LM; Lis E; Yao L; Rittle SL; Innocent N; Mullins DE; Boykow G; Reynolds IJ; Hill D; Parker EM; Hodgson RA
Eur J Pharmacol; 2014 Apr; 728():31-8. PubMed ID: 24486705
[TBL] [Abstract][Full Text] [Related]
20. Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
Vu CB; Pan D; Peng B; Kumaravel G; Smits G; Jin X; Phadke D; Engber T; Huang C; Reilly J; Tam S; Grant D; Hetu G; Petter RC
J Med Chem; 2005 Mar; 48(6):2009-18. PubMed ID: 15771443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
